
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
The American Journal of Managed Care
over 27 years ago
A New Physician's Guide to Evaluation Managed Care Opportunitiesover 27 years ago
Technology Assessment and the Drug Use Process





